ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Performance of The Plexur P™ Bone Void Filler Device in Patients Undergoing Iliac Crest Harvesting Procedures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00837473
Recruitment Status : Completed
First Posted : February 5, 2009
Results First Posted : April 30, 2018
Last Update Posted : April 30, 2018
Sponsor:
Information provided by (Responsible Party):
Medtronic Spinal and Biologics ( Osteotech, Inc )

Brief Summary:

The purpose of this study is to determine if Plexur P grows bone in the iliac crest (where bone was removed or "harvested") for the back surgery.

The study will be focusing on patients who require back surgery. Often additional bone is required from the hip of the patient (iliac crest). When bone removed from the hip, a "void" is often created. This "void" will be filled in with Osteotech's Plexur P product.


Condition or disease Intervention/treatment Phase
Iliac Crest Harvesting Procedure-Bone Void Filler Device: Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures Not Applicable

Detailed Description:

This prospective trial is designed to evaluate the ability of the Plexur P device (bone void filler) to reconstitute the iliac crest in patients requiring iliac crest bone harvesting procedures at one single study site.

Plexur P Bone Void Filler is:

  • A biocomposite of mineralized cortical allograft bone fibers and polylactide-co-glycolide co-polymer.
  • Designed to fill bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.
  • Porosity is introduced into the Plexur P Biocomposites to create a cancellous-like structure that provides a scaffold for bone growth.

In addition:

  • Patients will be screened for study eligibility based on the need for iliac crest bone harvesting.
  • Fifteen (15) eligible patients will be enrolled and will have an iliac crest harvesting defect backfilled with Plexur P to repair the iliac crest defect.
  • As a part of routine follow up care, patient related outcomes including measurements of pain severity and pain relief will be determined using patient (IRB approved) questionnaires.
  • Radiographic analysis will also be used to determine amount of bony ingrowth of the Plexur P device.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Pilot Study on the Performance of The Plexur P™ Bone Void Filler
Study Start Date : January 2009
Actual Primary Completion Date : March 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Plexur-P Bone Void Filler
Single arm. Open Label.
Device: Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures



Primary Outcome Measures :
  1. Number of Participants With Reconstitution of Bone Growth in the Iliac Crest Bone Void Determined by an Independent Radiologist [ Time Frame: 6 wks, 3 mths, 6 mths 12 mths, and 24 mths ]

    Reconstitution of bone growth was determined by an independent radiologist based on bony ingrowth and absence of a gap according to the following criteria:

    • Absent: limited or no bone mineralization visualized at the defect site; extensive areas of radiolucency.
    • Mild: identifiable bone mineralization and coalescence of the bone graft mass of < 50% of the defect site.
    • Moderate: identifiable bone mineralization and coalescence of the bone graft mass over > 50% of the defect site; some remaining unmineralized areas of radiolucency; limited evidence of partial bone remodeling and trabeculation.
    • Extensive: > 75% of bone mineralization over the defect site showing a contiguous and completely coalesced bone graft mass with confluent trabecular pattern.


Secondary Outcome Measures :
  1. General Health Status [ Time Frame: Baseline, 6 wks, 3 mths, 6 mths, 12 mths, and 24 mths ]
    The general health status was assessed by Medical Outcomes Study 36-Item Short Form Health Survey (SF-36v2). The SF-36v2 questionnaire contains 36 questions pertaining to eight subscales of health status. These eight subscales can be summarized as relating to either physical health or mental health. The physical component summary (PCS) is based primarily on the physical functioning, role-physical, bodily pain, and general health scales of the SF-36v2 survey. The mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. The score for PCS and MCS is between 0 and 100, with higher scores denoting better quality of life.

  2. Oswestry Disability Index [ Time Frame: Baseline, 6 wks, 3 mths, 6 mths, 12 mths, and 24 mths ]
    The Oswestry Disability Index (ODI) is an internationally validated questionnaire consisting of ten sets of statements which focus on pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and ability to travel. ODI scores are in a range of 0 to 100, with a lower score indicating less pain and disability and higher scores indicating more pain and disability.

  3. Pain Status Assessed by Visual Analog Scale (VAS) [ Time Frame: Baseline, 6 wks, 3 mths, 6 mths, 12 mths, and 24 mths ]
    The visual analog scale (VAS) was used for assessing pain status in the body locations of back/neck, left leg/arm, and right arm/leg. Subjects were asked to rate their perception of pain in VAS, generated by the Osteotech Clinical Department. The scale from 1 to 5 represented the pain levels at none, mild, average, severe, and extreme.

  4. Surgical Related Outcome--locations of Iliac Crest Bone Harvest [ Time Frame: During the time of operation, a range of 2.5-8.5 hrs ]
  5. Surgical outcome-the Amount of Cancellous Bone Harvested [ Time Frame: During the time of operation, a range of 2.5-8.5 hrs ]
  6. Surgical Outcome--operative Time [ Time Frame: The time of operation, a range of 2.5-8.5 hrs ]
  7. Surgical Outcome--blood Loss [ Time Frame: During the time of operation, a range of 2.5-8.5 hrs ]
  8. Surgical Outcome--length of Hospital Stay [ Time Frame: From admission to discharge, a range of 2 to 20 days ]
  9. Surgical Outcome- the Amount of Plexur™ P Product Utilized for Filling Void [ Time Frame: During the time of operation, a range of 2.5-8.5 hrs ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient is at least 18 yrs old.
  • The patient requires an iliac crest harvesting procedure.
  • The patient has signed an Informed Consent, approved by the IRB.

Exclusion Criteria:

  • Patient is less than 18 years old.
  • Patient presents with a bony void or gap in an area other than the iliac crest and/or has an infection present at the (operative) site.
  • Insulin dependent diabetics and/or in the opinion of the investigator, has poorly controlled non-insulin dependent diabetes.
  • The patient is a smoker.
  • The patient is mentally compromised (e.g., currently being treated from a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) and/or in the opinion of the investigator, is not likely to complete follow up visits;
  • The patient has a bleeding disorder of any etiology, severe vascular or neurological disease;
  • The patient has hypercalcemia and/or severe degenerative bone disease;
  • The patient has a history of long term steroid use;
  • The patient requires immunosuppressive therapy;
  • The patient has a history of drug or alcohol abuse that may interfere with his/her ability to provide written informed consent;
  • The patient is pregnant at the time of study entry or may likely become pregnant during the course of study participation;
  • The subject has an implanted device, which is incompatible with the use of imaging equipment;
  • The patient has an allergy to one of the components of the investigational device;
  • The patient has renal insufficiency;
  • The patient has a terminal illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00837473


Locations
United States, New York
Hospital for Special Surgery
New York, New York, United States, 10021
Sponsors and Collaborators
Osteotech, Inc
Investigators
Principal Investigator: Oheneba Boachie-Adijei, MD Hospital for Special Surgery, New York

Responsible Party: Osteotech, Inc
ClinicalTrials.gov Identifier: NCT00837473     History of Changes
Other Study ID Numbers: Trial #3206
First Posted: February 5, 2009    Key Record Dates
Results First Posted: April 30, 2018
Last Update Posted: April 30, 2018
Last Verified: September 2012

Keywords provided by Medtronic Spinal and Biologics ( Osteotech, Inc ):
Bone Void Filler
Iliac Crest Bone Void Filler
Back Surgery and Autograft Bone
Autograft Bone
Allograft Bone